(Q37974497)

26 August 2017

title

SLE in 2011: Deciphering the role of NETs and networks in SLE. (English)

1 reference

26 August 2017

Thomas Dörner

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Nature Reviews Rheumatology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

68-70

1 reference

Dissecting the immune cell mayhem that drives lupus pathogenesis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Neutrophil extracellular traps kill bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Mechanisms of B cell autoimmunity in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

AIRE regulates T-cell-independent B-cell responses through BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.200

21 January 2018

Identifiers

DOI

10.1038/NRRHEUM.2011.200

1 reference

26 August 2017

1 reference